High treatment satisfaction with Hizentra, a 20% subcutaneous immunoglobulin (SCIG): real-world survey data
Monday, March 5, 2018
South Hall A2 (Convention Center)
Jacob M. Romano, PharmD, RPh, BS, Rajiv Mallick, PhD
RATIONALE: To investigate treatment satisfaction of patients on SCIG (specifically Hizentra) from a large survey of Immune Deficiency Foundation (IDF) members diagnosed with primary immunodeficiency (PI).

METHODS: Between March 10 to 31 2017, an online survey was completed by patients and caregivers of pediatric patients with PI receiving IG therapy, from the IDF database. We analyzed the Treatment Satisfaction Questionnaire for Medication (TSQM) (effectiveness, side effects, convenience and global satisfaction) for patients currently receiving Hizentra. TSQM respondent scores are transformed to a 0–100 scale (0: poorest satisfaction, 100: perfect satisfaction). Desirable thresholds for treatment satisfaction (defined as the two best scores for side effects [1–5 scale]; and three best for all other domains [1–7 scale]) translated to 67, 75, 67, 67 and 69 for effectiveness, side effects, convenience, global satisfaction and total TSQM score, respectively.

RESULTS: Of 1,037 respondents, 744 were receiving IG; 247 were on Hizentra and completed the TSQM. Mean (standard deviation) scores were 73 (19) for effectiveness, 83 (24) for side effects, 72 (17) for convenience, 80 (16) for global satisfaction and 76 (14) for total TSQM score. Percentage of responders whose scores were above the desired threshold were 72% for the total TSQM score, 74% for effectiveness, 73% for side effects, 68% for convenience, and 85% for global satisfaction. When stratified by primary treatment decision maker (Prescriber, Patient, Other) no significant differences were seen in TSQM scores.

CONCLUSIONS: Generally, patients receiving Hizentra were highly satisfied with treatment, with 68–85% reporting above the desired thresholds with TSQM.